NCT00216528 – A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta) Posted on March 18, 2019 by tsuperadmin -
NCT01050582 – Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Posted on December 20, 2018 by tsuperadmin -
NCT00236379 – A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder Posted on December 20, 2018 by tsuperadmin -
NCT00216632 – Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR) Posted on December 20, 2018 by tsuperadmin -
NCT00369239 – Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta? Posted on December 20, 2018 by tsuperadmin -
NCT00216671 – Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode Posted on December 20, 2018 by tsuperadmin -
NCT01258920 – A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia Posted on November 27, 2018 by tsuperadmin -
NCT01299389 – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia Posted on November 27, 2018 by tsuperadmin -
NCT01527305 – An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia Posted on November 27, 2018 by tsuperadmin -
NCT01051531 – Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics Posted on November 27, 2018 by tsuperadmin -